Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…Abstract Number: 1683 • 2014 ACR/ARHP Annual Meeting
Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Background/Purpose Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional…Abstract Number: 1699 • 2014 ACR/ARHP Annual Meeting
Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon
Background/Purpose Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation…Abstract Number: 1701 • 2014 ACR/ARHP Annual Meeting
Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Background/Purpose Iloprost is a milestone in the treatment of Raynaud’s Phenomenon (RP). However, it has transient hemodynamic effects due to a very short half-time, thereby…Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…Abstract Number: 737 • 2014 ACR/ARHP Annual Meeting
Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy
Background/Purpose Nailfold videocapillaroscopy allows non-invasive assessment of the microcirculation. Image annotation software allows tracking of changes over time; a potential outcome measure for systemic sclerosis…Abstract Number: 523 • 2014 ACR/ARHP Annual Meeting
Serum CXCL4 Is Increased in Patients with Primary Sjögren’s Syndrome and Is Associated with Features of Microvascular Impairment
Background/Purpose CXCL4 is a pleiotropic antiangiogenic and immunomodulatory chemokine. We aimed to investigate CXCL4 serum levels in primary Sjögren’s syndrome (pSS) and looked for associations…Abstract Number: 2596 • 2013 ACR/ARHP Annual Meeting
Association Between Nail Fold Capillaroscopy Abnormalities and Thermographic Assessment Of Peripheral Microvascular Dysfunction In An Unselected Cohort Of Patients Under Investigation For Symptoms Of Raynaud’s Phenomenon
Background/Purpose: Nail fold capillaroscopy (NC) and infrared thermography (IRT) allow objective assessment of digital microvascular abnormalities in patients with Raynaud’s phenomenon (RP) and have an…Abstract Number: 2597 • 2013 ACR/ARHP Annual Meeting
Acupressure For The Treatment Of Raynaud’s Phenomenon: A Pilot Randomized Controlled Trial
Background/Purpose: Raynaud’s phenomenon (RP) affects approximately 10% of the US population. The high cost, lack of efficacy, and side effects of conventional medical therapies necessitates…Abstract Number: 2598 • 2013 ACR/ARHP Annual Meeting
Timing and Outcome Of Transition From Primary To Secondary Raynaud’s Phenomenon: A Capillaroscopic Based Study
Background/Purpose: Raynaud's phenomenon (RP) is classified as primary (PRP) or secondary (SRP) depending on its association with an underlying disease (1,2). PRP can evolve to…Abstract Number: 2179 • 2013 ACR/ARHP Annual Meeting
Consensus: What Agent To Use When First-Line Vasodilatadors Fail In Raynaud´s Phenomenon Or Digital Ulcers Secondary To Juvenile Systemic Sclerosis?
Background/Purpose: Juvenile Systemic Sclerosis (JSS) is characterized by Raynaud`s phenomenon (RP) and digital ulcers (DU).Conventional therapy includes calcium channel blockers (CCB). A growing number of…Abstract Number: 1813 • 2013 ACR/ARHP Annual Meeting
Evaluation Of The Effect Of Sildenafil On The Microvascular Blood Flow and On The Endothelial Progenitor Cells In Patients With Early Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
Background/Purpose: Phosphodiesterase-5 inhibitors have been successfully used for the treatment of Raynaud’s phenomenon (RP) in patients with systemic sclerosis (SSc). However, no study has evaluated…Abstract Number: 853 • 2013 ACR/ARHP Annual Meeting
Capillaroscopy Compared With Color Doppler Ultrasound Of Digital Arteries For Distinguishing Primary From Secondary Raynaud’s Phenomenon
Background/Purpose: Raynaud’s phenomenon (RP) is commonly seen in rheumatology practice. Differentiating primary from secondary RP is important for disease management and prognosis. How does capillaroscopy…Abstract Number: 703 • 2013 ACR/ARHP Annual Meeting
Correlation Between Patient Self-Report Of Symptoms Of Raynaud’s Phenomenon and Objective Assessment Of Digital Microvascular Perfusion Using Infrared Thermography
Background/Purpose: Patient self-report of digital colour changes form the basis of a clinical diagnosis of Raynaud's phenomenon (RP) and help classify patients with early systemic…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- Next Page »